What we do

Creating New Standards for Stain-free Digital Pathology

We are an innovative global MedTech company that specializes in stain-free digital pathology and sophisticated computational analysis for drug development and clinical diagnosis. We use stain-free biophotonic imaging and an AI digital pathology platform to provide granular visualizations at high resolutions and quantify morphological features of fibrosis within tissues in a consistent and reproducible manner.

Our Founders

"Historically, biopsies have been taken, stained, and assessed in the same way by observing the tissues under the microscope. However, this is intrinsically a subjective approach and is often prone to inconsistencies and variabilities introduced by staining. HistoIndex was founded with the mission to pioneer biophotonics technologies that provide unprecedented biological insights in order to further precision diagnostics and therapies."
HistoIndex CEO Gideon Ho
Dr. Gideon Ho
Co-founder and CEO
“The future of medicine will be transformed by platforms that extract deeper dimensions of biological data from tissue. Our roadmap focuses on integrating new modalities with our proprietary techniques to achieve an unprecedented level of insight. We aim to continue pushing the boundaries of what's possible in tissue analysis to equip our partners with the clarity needed to improve diagnostic development and therapeutic success.”
Dr. Dean Tai
Co-founder and CSO

Our Milestones

2010
Spun off from Agency of Science, Technology and Research (A*STAR), Singapore.
2013
Launched Genesis®200 Imaging System - World’s first stain-free multiphoton imaging system
2014
Established subsidiary company in Hangzhou, China
2015
Patented Method of detecting fibrous tissue using co-localized images generated by Second Harmonic Generation
2017
Established Scientific advisory board and received Frost & Sullivan Asia-Pacific Best Practices Award for Innovative Diagnostics
2019
Launched Centre of Excellence with ILBS in New Delhi for Advanced Diagnostics and Clinical Research on NASH
2020
Recommended as a validated quantification tool in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China
2021
Demonstrated concomitant post-treatment improvements in liver fat and fibrosis in Novartis’ NASH Phase 2 Clinical Trial
2022
Established UK Office for European Market Expansion.
2022
Published landmark consensus paper on qBallooning as a reproducible approach and potential clinical trial endpoint.
2022
Recruited as primary, secondary, and exploratory endpoints in Renegeron’s NASH Phase 2 Clinical Trial.
2023
David John Jeans, life sciences and medtech visionary, joins as Board Chairman.
2023
Demonstrated superior results in Madrigal’s Resmetirom Phase 3 clinical trial.

Our International Imaging Centers

HistoIndex Headquarters
Singapore

HistoIndex China Subsidiary Office
Zhejiang, China

HistoIndex UK Branch
Glasgow, UK

Institute of Liver and Biliary Science (ILBS)
Delhi, India

Imaging Centre

Summit Clinical Research, 
Texas, USA

Imaging Centre 

Pinnacle Clinical Research, 
Texas, USA

Imaging Centre 

Virginia Commonwealth University
Virginia, USA

Imaging Centre and Academic Research Partner

ICON Clinical Research
New York, USA

Imaging Centre

Our Partners

Academic Research Partners
Baylor College of Medicine
Cincinnati Children’s Hospital Medical Center
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Centre
Monash University
Mount Sinai (Icahn School of Medicine)
National University Hospital, Singapore
Newcastle University
Peking University People’s Hospital
Pitié-Salpêtrière Hospital
Singapore General Hospital
University of Cambridge
University of Edinburgh
University of Melbourne
University of Oxford
Virginia Commonwealth University
Academic Research Partners
Baylor College of Medicine
Cincinnati Children’s Hospital Medical Center
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Centre
Monash University
Mount Sinai (Icahn School of Medicine)
National University Hospital, Singapore
Newcastle University
Peking University People’s Hospital
Pitié-Salpêtrière Hospital
Singapore General Hospital
University of Cambridge
University of Edinburgh
University of Melbourne
University of Oxford
Virginia Commonwealth University
Selected Industry Partners
Bristol Myers Squibb
Galectin Therapeutics
Madrigal Pharmaceuticals
Novartis
Sagimet Biosciences
Takeda Pharmaceuticals
Selected Industry Partners
Bristol Myers Squibb
Galectin Therapeutics
Madrigal Pharmaceuticals
Novartis
Sagimet Biosciences
Takeda Pharmaceuticals